 |
| |
| Sep-25-18 | Downgrade |
Raymond James |
Strong Buy → Outperform |
|
|
| Mar-09-18 | Reiterated |
B. Riley FBR, Inc. |
Buy |
$21.50 → $27 |
|
| Dec-01-17 | Resumed |
B. Riley FBR, Inc. |
Buy |
$21.50 |
|
| Nov-14-17 | Resumed |
H.C. Wainwright |
Buy |
$33 |
|
| Apr-25-17 | Initiated |
Jefferies |
Buy |
|
|
| Mar-06-17 | Reiterated |
FBR & Co. |
Outperform |
$24 → $26 |
|
| Oct-06-16 | Resumed |
Brean Capital |
Buy |
$28 |
|
| May-27-16 | Initiated |
SunTrust |
Buy |
$18 |
|
| Dec-01-15 | Initiated |
FBR Capital |
Outperform |
$29 |
|
| Sep-09-15 | Initiated |
Raymond James |
Strong Buy |
|
|
| Aug-12-15 | Resumed |
H.C. Wainwright |
Buy |
$22 |
|
| Jun-19-15 | Reiterated |
Brean Capital |
Buy |
$22 → $28 |
|
| Dec-11-14 | Reiterated |
ROTH Capital |
Buy |
$25 → $33 |
|
| Dec-10-14 | Reiterated |
ROTH Capital |
Buy |
$25 → $33 |
|
| Oct-27-14 | Initiated |
H.C. Wainwright |
Buy |
$17 |
|
| Sep-25-14 | Reiterated |
Brean Capital |
Buy |
$19 → $22 |
|
| Jul-22-14 | Reiterated |
Brean Capital |
Buy |
$13 → $19 |
|
| Jul-02-14 | Reiterated |
MLV & Co |
Buy |
$10 → $16 |
|
| Apr-04-14 | Initiated |
Brean Capital |
Buy |
$13 |
|
| Mar-07-14 | Reiterated |
MLV & Co |
Buy |
$9 → $11 |
|
|
|
| Oct-22-18 02:19PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CBS, COCP, TGTX and TRVN GlobeNewswire |
| 12:32PM | IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE |
| Oct-21-18 11:00AM | SHAREHOLDER ALERT: AMPE NVRO PZZA OPK QRTEA MCHP COCP TGTX CPB TRVN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire |
| Oct-19-18 06:41PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of TG Therapeutics, Inc. - TGTX GlobeNewswire |
| 02:45PM | INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE |
| Oct-18-18 11:40AM | CLASS ACTION UPDATE for TGTX, MGTI, SFIX and GOOG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire |
| 10:00AM | SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TG Therapeutics, Inc. (TGTX) GlobeNewswire |
| Oct-17-18 05:53PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX PR Newswire |
| 02:00PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PZZA, TGTX, MGTI, CHGG and GOOG GlobeNewswire |
| Oct-16-18 07:01PM | Glancy Prongay & Murray LLP Announces Investigation on Behalf of TG Therapeutics, Inc. Investors (TGTX) Business Wire |
| 06:00PM | SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE |
| 04:15PM | TG THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against TG Therapeutics, Inc. GlobeNewswire |
| 07:50AM | Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire |
| Oct-15-18 03:35PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PDD, QRTEA, TRCO, MCHP, TGTX and CPB GlobeNewswire |
| 01:10PM | TG THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In TG Therapeutics, Inc. To Contact The Firm Business Wire |
| Oct-14-18 10:05AM | SHAREHOLDER ALERT: QRTEA TRCO PVG USAT COCP TGTX ABBV CPB CHGG ACHC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire |
| Oct-12-18 06:16PM | TGTX LOSS NOTICE: Rosen Law Firm Reminds TG Therapeutics, Inc. Investors of Important Deadline in Class Action TGTX Business Wire |
| 02:00PM | Johnson Fistel Files Class Action Suit against TG Therapeutics, Inc. PR Newswire |
| 01:00PM | CLASS ACTION UPDATE for TGTX and CPB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire |
| Oct-11-18 05:15PM | IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE |
| 04:28PM | INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of TG Therapeutics, Inc. Investors (TGTX) Business Wire |
| 03:34PM | Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against TG Therapeutics, Inc. Business Wire |
| 02:22PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, TGTX, HAS and CPB GlobeNewswire |
| 11:00AM | TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the 34th Congress of ECTRIMS GlobeNewswire |
| Oct-10-18 07:31PM | Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MGT Capital, Applied Optoelectronics, and TG Therapeutics and Encourages Investors to Contact the Firm GlobeNewswire |
| 02:59PM | SHAREHOLDER ALERT: LCI CBS PZZA LOGM QRTEA PVG TGTX HAS CPB ACHC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire |
| 01:20PM | IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE |
| 12:26PM | Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against TG Therapeutics, Inc. (TGTX) PR Newswire |
| 10:00AM | SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TG Therapeutics, Inc. (TGTX) GlobeNewswire |
| 09:00AM | Why TG Therapeutics Stock Collapsed Last Month Motley Fool |
| Oct-09-18 04:34PM | TG THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against TG Therapeutics, Inc. GlobeNewswire +6.45% |
| 03:16PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TGTX, HAS, ACHC and ADNT GlobeNewswire |
| 02:35PM | TG THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In TG Therapeutics, Inc. To Contact The Firm ACCESSWIRE |
| 10:45AM | IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE |
| 09:41AM | 3 Biotech Stocks With Major Incoming Catalysts Motley Fool |
| Oct-08-18 04:18PM | Robbins Arroyo LLP: TG Therapeutics, Inc. (TGTX) Misled Shareholders According to a Class Action Business Wire |
| 02:30PM | CLASS ACTION UPDATE for TGTX and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire |
| 12:30PM | INVESTOR ALERT: Ademi & O'Reilly, LLP Reminds Investors in TG Therapeutics, Inc. (TGTX) of December 3 Deadline PR Newswire |
| 10:25AM | IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire |
| 07:30AM | The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs Benzinga |
| 07:30AM | TG Therapeutics, Inc. Highlights Schedule of Events at the Upcoming 34th Congress of ECTRIMS GlobeNewswire |
| Oct-05-18 08:00PM | Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. (TGTX) GlobeNewswire |
| 04:30PM | TG THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In TG Therapeutics, Inc. To Contact The Firm PR Newswire |
| 03:10PM | IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire |
| 02:42PM | How Does TG Therapeutics Inc (NASDAQ:TGTX) Affect Your Portfolio Returns? Simply Wall St. |
| 11:11AM | EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against TG Therapeutics, Inc. Business Wire |
| 10:00AM | SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against TG Therapeutics, Inc. (TGTX) GlobeNewswire |
| Oct-04-18 08:06PM | Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. (TGTX) and Encourages TGTX Investors to Contact the Firm GlobeNewswire |
| 06:50PM | Kaskela Law LLC Announces Shareholder Class Action Lawsuit Filed Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm TGTX GlobeNewswire |
| 05:11PM | Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against TG Therapeutics, Inc. Business Wire |
| 03:51PM | SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against TG Therapeutics, Inc. (TGTX) PR Newswire |
| Sep-28-18 10:05AM | TG Therapeutics (TGTX) in Focus: Stock Moves 8.6% Higher Zacks |
| 07:30AM | TG Therapeutics, Inc. to Present at Upcoming Investor Conferences GlobeNewswire |
| Sep-26-18 04:56PM | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of TG Therapeutics, Inc. GlobeNewswire |
| 08:00AM | Today's Research Reports on Trending Tickers: Jaguar Health and TG Therapeutics ACCESSWIRE |
| 08:00AM | TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Accepted for Oral Presentation at the Upcoming 34th Congress of ECTRIMS GlobeNewswire |
| 01:00AM | TG Therapeutics (TGTX) Alert: Johnson Fistel Investigates TG Therapeutics, Inc.; Investors Encouraged to Contact the Firm PR Newswire |
| Sep-25-18 11:39AM | A Big Disappointment Sends TG Therapeutics Stock Skidding 34% Today Motley Fool -44.32% |
| 07:00AM | TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial GlobeNewswire |
| Sep-21-18 08:46AM | Implied Volatility Surging for TG Therapeutics (TGTX) Stock Options Zacks |
| Sep-18-18 08:00AM | Todays Research Reports on Stocks to Watch: Teva Pharmaceutical and TG Therapeutics ACCESSWIRE |
| Aug-26-18 03:40PM | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results Benzinga |
| Aug-23-18 11:50AM | New York City stocks that are driving Wall Street's latest bull run American City Business Journals |
| Aug-21-18 03:28AM | Edited Transcript of TGTX earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents +5.65% |
| Aug-20-18 08:39AM | Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock? Zacks |
| Aug-15-18 07:40AM | Consolidated Research: 2018 Summary Expectations for Allegiance Bancshares, TG Therapeutics, JELD-WEN Holding, Eagle Bulk Shipping, Bryn Mawr Bank, and Surmodics Fundamental Analysis, Key Performance Indications GlobeNewswire |
| Aug-13-18 08:17AM | 3 Biotech Stocks With Major Catalysts Incoming Motley Fool |
| Aug-07-18 04:17PM | TG Therapeutics: 2Q Earnings Snapshot Associated Press |
| 04:00PM | TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2018 Financial Results GlobeNewswire |
| 07:30AM | TG Therapeutics Announces Completion of Target Enrollment in the ULTIMATE Phase 3 Trials in Multiple Sclerosis GlobeNewswire |
| Aug-06-18 07:30AM | TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2018 Financial Results and Business Update GlobeNewswire |
| Jul-10-18 08:40AM | Implied Volatility Surging for TG Therapeutics (TGTX) Stock Options Zacks |
| 07:35AM | Complimentary Technical Snapshots on Trevena and Three More Biotech Stocks ACCESSWIRE |
| Jun-20-18 07:30AM | TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody GlobeNewswire |
| Jun-18-18 12:00PM | TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis at the 4th Congress of the European Academy of Neurology GlobeNewswire |
| 07:30AM | TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at the 23rd Congress of the European Hematology Association (EHA) GlobeNewswire |
| Jun-15-18 09:17AM | TG Therapeutics, Inc. Announces Clinical and Preclinical Data Presentations at the 23rd Congress of the European Hematology Association GlobeNewswire |
| 08:13AM | TG Therapeutics, Inc. Announces Oral Presentation of Umbralisib plus Ruxolitinib in Patients with Myelofibrosis at the 23rd Congress of the European Hematology Association GlobeNewswire |
| Jun-12-18 04:29PM | This Biotech Investors Picks Returned 31% in Q1; Here Are Its New Bets Insider Monkey |
| Jun-08-18 07:00AM | TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE |
| 06:04AM | 3 Cancer Stocks That Could Soar in the Second Half of 2018 Motley Fool |
| Jun-05-18 07:30AM | TG Therapeutics, Inc. to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire |
| Jun-04-18 04:06PM | ASCO 2018 Sends TG Therapeutics Stock Soaring 10% Today Motley Fool +10.78% |
| 09:00AM | TG Therapeutics, Inc. Announces Umbralisib Clinical Data Presentation at the 54th Annual Meeting of the American Society of Clinical Oncology GlobeNewswire |
| 07:30AM | TG Therapeutics, Inc. Appoints Adam Waldman as Chief Commercial Officer GlobeNewswire |
| Jun-01-18 07:30AM | TG Therapeutics, Inc. Recaps Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association GlobeNewswire |
| May-17-18 09:10AM | TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association GlobeNewswire |
| May-14-18 07:51PM | Edited Transcript of TGTX earnings conference call or presentation 8-May-18 12:30pm GMT Thomson Reuters StreetEvents +5.34% |
| May-08-18 07:53AM | TG Therapeutics: 1Q Earnings Snapshot Associated Press -6.51% |
| 07:30AM | TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2018 Financial Results GlobeNewswire |
| May-04-18 07:30AM | TG Therapeutics, Inc. to Host Conference Call on First Quarter 2018 Financial Results and Business Update GlobeNewswire |
| Apr-30-18 08:20AM | Recent Analysis Shows FTD Companies, TG Therapeutics, National HealthCare, Lennox International, PRA Group, and Unit Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
| Apr-24-18 08:06AM | TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Meeting GlobeNewswire |
| Apr-20-18 08:03AM | 3 Biotech Stocks With Major Catalysts Incoming Motley Fool |
| Apr-18-18 09:00AM | TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Companys BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire |
| Apr-16-18 07:00AM | Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline GlobeNewswire |
| Mar-26-18 07:30AM | TG Therapeutics, Inc. to Present at the Needham 17th Annual Healthcare Conference GlobeNewswire |
| Mar-15-18 07:30AM | TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire |
| Mar-09-18 02:21PM | Edited Transcript of TGTX earnings conference call or presentation 8-Mar-18 1:30pm GMT Thomson Reuters StreetEvents |
| Mar-08-18 09:36AM | TG Therapeutics reports 4Q loss Associated Press +7.87% |
|
|
|
|
| TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Power Sean A | CFO, Secretary and Treasurer | Jul 03 | Sale | 13.19 | 35,000 | 461,650 | 438,267 | Jul 05 05:00 PM | | Power Sean A | CFO, Secretary and Treasurer | Jul 02 | Sale | 13.26 | 12,191 | 161,653 | 473,267 | Jul 05 05:00 PM | | KENNEDY WILLIAM JAMES | Director | Jun 14 | Sale | 13.45 | 25,071 | 337,205 | 60,330 | Jun 18 04:30 PM | | Power Sean A | CFO, Secretary and Treasurer | Jan 02 | Sale | 8.50 | 32,006 | 272,051 | 485,458 | Jan 03 05:25 PM |
|
|
|
|
|
|
